NCT02262637

Brief Summary

Study to evaluate efficacy and tolerability of Micardis®/MicardisPlus® under usual daily-practice prescribing-conditions with emphasis on effects on endorgan damage in the clientele of cardiologists, nephrologists, and diabetologists

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,814

participants targeted

Target at P75+ for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2003

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2006

Completed
8.6 years until next milestone

First Submitted

Initial submission to the registry

October 10, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 13, 2014

Completed
Last Updated

October 13, 2014

Status Verified

October 1, 2014

Enrollment Period

2.5 years

First QC Date

October 10, 2014

Last Update Submit

October 10, 2014

Conditions

Hypertension

Outcome Measures

Primary Outcomes (2)

  • Change in systolic blood pressure (SBP)

    baseline, up to 6 months

  • Change in diastolic blood pressure (DBP)

    baseline, up to 6 months

Study Arms (3)

Hypertensive patients - Cardiologists

Drug: Micardis®Drug: MicardisPlus®

Hypertensive patients - Nephrologists

Drug: Micardis®Drug: MicardisPlus®

Hypertensive patients - Diabetologists

Drug: Micardis®Drug: MicardisPlus®

Interventions

Micardis®DRUG
Hypertensive patients - CardiologistsHypertensive patients - DiabetologistsHypertensive patients - Nephrologists
MicardisPlus®DRUG
Hypertensive patients - CardiologistsHypertensive patients - DiabetologistsHypertensive patients - Nephrologists

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Outpatients with hypertension recruited at Cardiologists, Nephrologists, Diabetologists

You may qualify if:

  • Age \>= 18 years

You may not qualify if:

  • Age \< 18 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypertension

Interventions

Telmisartantelmisartan, hydrochlorothiazide drug combination

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Biphenyl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 10, 2014

First Posted

October 13, 2014

Study Start

September 1, 2003

Primary Completion

March 1, 2006

Last Updated

October 13, 2014

Record last verified: 2014-10